Cargando…

Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance

Immuno-oncology is an emerging field in the treatment of oncological diseases, that is based on recruitment of the host immune system to attack the tumor. Radiation exposure may help to unlock the potential of the immune activating agents by enhancing the antigen release and presentation, attraction...

Descripción completa

Detalles Bibliográficos
Autores principales: Voronova, Veronika, Vislobokova, Anastasia, Mutig, Kerim, Samsonov, Mikhail, Peskov, Kirill, Sekacheva, Marina, Materenchuk, Maria, Bunyatyan, Natalya, Lebedeva, Svetlana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760959/
https://www.ncbi.nlm.nih.gov/pubmed/36544712
http://dx.doi.org/10.3389/fonc.2022.1035884
_version_ 1784852599823925248
author Voronova, Veronika
Vislobokova, Anastasia
Mutig, Kerim
Samsonov, Mikhail
Peskov, Kirill
Sekacheva, Marina
Materenchuk, Maria
Bunyatyan, Natalya
Lebedeva, Svetlana
author_facet Voronova, Veronika
Vislobokova, Anastasia
Mutig, Kerim
Samsonov, Mikhail
Peskov, Kirill
Sekacheva, Marina
Materenchuk, Maria
Bunyatyan, Natalya
Lebedeva, Svetlana
author_sort Voronova, Veronika
collection PubMed
description Immuno-oncology is an emerging field in the treatment of oncological diseases, that is based on recruitment of the host immune system to attack the tumor. Radiation exposure may help to unlock the potential of the immune activating agents by enhancing the antigen release and presentation, attraction of immunocompetent cells to the inflammation site, and eliminating the tumor cells by phagocytosis, thereby leading to an overall enhancement of the immune response. Numerous preclinical studies in mouse models of glioma, murine melanoma, extracranial cancer, or colorectal cancer have contributed to determination of the optimal radiotherapy fractionation, as well as the radio- and immunotherapy sequencing strategies for maximizing the antitumor activity of the treatment regimen. At the same time, efficacy of combined radio- and immunotherapy has been actively investigated in clinical trials of metastatic melanoma, non-small-cell lung cancer and renal cell carcinoma. The present review summarizes the current advancements and challenges related to the aforementioned treatment approach.
format Online
Article
Text
id pubmed-9760959
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97609592022-12-20 Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance Voronova, Veronika Vislobokova, Anastasia Mutig, Kerim Samsonov, Mikhail Peskov, Kirill Sekacheva, Marina Materenchuk, Maria Bunyatyan, Natalya Lebedeva, Svetlana Front Oncol Oncology Immuno-oncology is an emerging field in the treatment of oncological diseases, that is based on recruitment of the host immune system to attack the tumor. Radiation exposure may help to unlock the potential of the immune activating agents by enhancing the antigen release and presentation, attraction of immunocompetent cells to the inflammation site, and eliminating the tumor cells by phagocytosis, thereby leading to an overall enhancement of the immune response. Numerous preclinical studies in mouse models of glioma, murine melanoma, extracranial cancer, or colorectal cancer have contributed to determination of the optimal radiotherapy fractionation, as well as the radio- and immunotherapy sequencing strategies for maximizing the antitumor activity of the treatment regimen. At the same time, efficacy of combined radio- and immunotherapy has been actively investigated in clinical trials of metastatic melanoma, non-small-cell lung cancer and renal cell carcinoma. The present review summarizes the current advancements and challenges related to the aforementioned treatment approach. Frontiers Media S.A. 2022-12-05 /pmc/articles/PMC9760959/ /pubmed/36544712 http://dx.doi.org/10.3389/fonc.2022.1035884 Text en Copyright © 2022 Voronova, Vislobokova, Mutig, Samsonov, Peskov, Sekacheva, Materenchuk, Bunyatyan and Lebedeva https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Voronova, Veronika
Vislobokova, Anastasia
Mutig, Kerim
Samsonov, Mikhail
Peskov, Kirill
Sekacheva, Marina
Materenchuk, Maria
Bunyatyan, Natalya
Lebedeva, Svetlana
Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
title Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
title_full Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
title_fullStr Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
title_full_unstemmed Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
title_short Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
title_sort combination of immune checkpoint inhibitors with radiation therapy in cancer: a hammer breaking the wall of resistance
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9760959/
https://www.ncbi.nlm.nih.gov/pubmed/36544712
http://dx.doi.org/10.3389/fonc.2022.1035884
work_keys_str_mv AT voronovaveronika combinationofimmunecheckpointinhibitorswithradiationtherapyincancerahammerbreakingthewallofresistance
AT vislobokovaanastasia combinationofimmunecheckpointinhibitorswithradiationtherapyincancerahammerbreakingthewallofresistance
AT mutigkerim combinationofimmunecheckpointinhibitorswithradiationtherapyincancerahammerbreakingthewallofresistance
AT samsonovmikhail combinationofimmunecheckpointinhibitorswithradiationtherapyincancerahammerbreakingthewallofresistance
AT peskovkirill combinationofimmunecheckpointinhibitorswithradiationtherapyincancerahammerbreakingthewallofresistance
AT sekachevamarina combinationofimmunecheckpointinhibitorswithradiationtherapyincancerahammerbreakingthewallofresistance
AT materenchukmaria combinationofimmunecheckpointinhibitorswithradiationtherapyincancerahammerbreakingthewallofresistance
AT bunyatyannatalya combinationofimmunecheckpointinhibitorswithradiationtherapyincancerahammerbreakingthewallofresistance
AT lebedevasvetlana combinationofimmunecheckpointinhibitorswithradiationtherapyincancerahammerbreakingthewallofresistance